276 related articles for article (PubMed ID: 25547681)
1. Recent progress in dengue vaccine development.
Wei J; Chen H; An J
Virol Sin; 2014 Dec; 29(6):353-63. PubMed ID: 25547681
[TBL] [Abstract][Full Text] [Related]
2. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
3. Current progress in dengue vaccines.
Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
[TBL] [Abstract][Full Text] [Related]
4. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
5. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
7. [Research progress in the structure and function of dengue virus non-structural 1 protein].
Chen Y; Ren RW; Liu JW
Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
[TBL] [Abstract][Full Text] [Related]
8. Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.
Borges MB; Marchevsky RS; Carvalho Pereira R; da Silva Mendes Y; Almeida Mendes LG; Diniz-Mendes L; Cruz MA; Tahmaoui O; Baudart S; Freire M; Homma A; Schneider-Ohrum K; Vaughn DW; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
PLoS Pathog; 2019 Apr; 15(4):e1007721. PubMed ID: 31009499
[TBL] [Abstract][Full Text] [Related]
9. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
10. Dengue vaccine development by the year 2020: challenges and prospects.
Wilder-Smith A
Curr Opin Virol; 2020 Aug; 43():71-78. PubMed ID: 33086187
[TBL] [Abstract][Full Text] [Related]
11. Mouse models of dengue virus infection and disease.
Yauch LE; Shresta S
Antiviral Res; 2008 Nov; 80(2):87-93. PubMed ID: 18619493
[TBL] [Abstract][Full Text] [Related]
12. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
13. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections.
Kitab B; Kohara M; Tsukiyama-Kohara K
Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688
[TBL] [Abstract][Full Text] [Related]
14. Dengue virus vaccine development.
Yauch LE; Shresta S
Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
[TBL] [Abstract][Full Text] [Related]
15. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
16. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
17. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2.
Stauft CB; Song Y; Gorbatsevych O; Pantoja P; Rodriguez IV; Futcher B; Sariol CA; Wimmer E
Virology; 2019 Nov; 537():237-245. PubMed ID: 31539771
[TBL] [Abstract][Full Text] [Related]
18. Dengue vaccine: an update on recombinant subunit strategies.
Martin J; Hermida L
Acta Virol; 2016 Mar; 60(1):3-14. PubMed ID: 26982462
[TBL] [Abstract][Full Text] [Related]
19. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
